Hosta

by | Mar 16, 2018 | Hosta

How Can We Help?
You are here:
< Back

Radalbuvir (INN,[1] also known as GS-9669) is an experimental antiviral drug for the treatment of hepatitis C virus (HCV) infection developed by Gilead Sciences. Radalbuvir acts as an NS5B inhibitor. It is currently in clinical trials.[2] It targets NS5B polymerase.[3]

References

  1. ^ "International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. Vol. 28, no. 4. 2014. Archived from the original (PDF) on 2015-04-02.
  2. ^ "Search of: GS-9669 — List Results". ClinicalTrials.gov.
  3. ^ Borgia G, Maraolo AE, Nappa S, Gentile I, Buonomo AR (March 2018). "NS5B polymerase inhibitors in phase II clinical trials for HCV infection". Expert Opinion on Investigational Drugs. 27 (3): 243–250. doi:10.1080/13543784.2018.1420780. PMID 29271672. S2CID 3672885.
Categories
Table of Contents